

SENATE No. 689

The Commonwealth of Massachusetts

PRESENTED BY:

John F. Keenan

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act relative to the care and treatment of patients with mitochondrial disease.

PETITION OF:

NAME:

John F. Keenan
Crystal Evans

DISTRICT/ADDRESS:

Norfolk and Plymouth

SENATE No. 689

By Mr. Keenan, a petition (accompanied by bill, Senate, No. 689) of John F. Keenan and Crystal Evans for legislation relative to the care and treatment of patients with mitochondrial disease. Financial Services.

[SIMILAR MATTER FILED IN PREVIOUS SESSION
SEE SENATE, NO. 603 OF 2019-2020.]

The Commonwealth of Massachusetts

**In the One Hundred and Ninety-Second General Court
(2021-2022)**

An Act relative to the care and treatment of patients with mitochondrial disease.

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

1 SECTION 1. Chapter 32A of the General Laws, as appearing in the 2018 Official
2 Edition, is hereby amended by inserting after Section 17Q the following section:-

3 Section 17R. The commission shall provide to any active or retired employee of the
4 commonwealth or spouse/dependent who is insured under the group insurance commission,
5 coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited
6 to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin
7 C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

8 SECTION 2. Chapter 175 of the General Laws, as appearing in the 2018 Official Edition,
9 is hereby amended by inserting after Section 47KK the following section:-

10 Section 47LL. Any policy, contract, agreement, plan or certificate of insurance issued,
11 delivered or renewed within the commonwealth shall provide coverage for treatment of
12 mitochondrial disease. Said treatment shall include, but not be limited to, the use of
13 vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin
14 B1, Vitamin B2, Vitamin K1 and L-Carnitine.

15 SECTION 3. Chapter 176A of the General Laws, as appearing in the 2018 Official
16 Edition, is hereby amended by inserting after Section 8MM the following section:-

17 Section 8NN. Any contract between a subscriber and a corporation under an individual or
18 group hospital service plan delivered, issued or renewed within the commonwealth shall provide
19 coverage for treatment of mitochondrial disease. Said treatment shall include, but not be limited
20 to, the use of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin
21 C, Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.

22 SECTION 4. Chapter 176B of the General Laws, as appearing in the 2018 Official
23 Edition, is hereby amended by inserting after Section 4MM the following section:-

24 Section 4NN. Any subscription certificate under an individual or group medical service
25 agreement delivered, issued or renewed within the commonwealth shall provide coverage for
26 treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use of
27 vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C, Vitamin
28 B1, Vitamin B2, Vitamin K1 and L-Carnitine.

29 SECTION 5. Chapter 176G of the General Laws, as appearing in the 2018 Official
30 Edition, is hereby amended by inserting after Section 4EE the following section:-

31 Section 4FF. Any individual or group health maintenance contract shall provide coverage
32 for treatment of mitochondrial disease. Said treatment shall include, but not be limited to, the use
33 of vitamin and nutritional supplements, such as CoEnzyme Q10, Vitamin E, Vitamin C,
34 Vitamin B1, Vitamin B2, Vitamin K1 and L-Carnitine.